Hypertriglyceridaemia Severity Interpreter
Hypertriglyceridaemia Severity Interpreter
Grade a triglyceride result as mild, moderate, severe or very severe on the Endocrine Society classification, in mg/dL or mmol/L, and see which bands matter for cardiovascular risk and which one is about pancreatitis. Where other guidelines draw the pancreatitis line somewhere else, the page says so.
How high is this triglyceride, and is it a pancreatitis risk?
Triglyceride + unit → severity and pancreatitis riskFasting triglyceride 640 mg/dL in a man with poorly controlled type 2 diabetes who drinks heavily.
Endocrine Society classification
Mild: 150–199 mg/dL (1.7–2.3) — cardiovascular risk
Moderate: 200–999 mg/dL (2.3–11.3) — cardiovascular risk
Severe: 1,000–1,999 mg/dL (11.3–22.6) — pancreatitis risk
Very severe: 2,000 mg/dL (22.6) or above — pancreatitis risk
mmol/L × 88.57 = mg/dL
- 88.57
- mg/dL per mmol/L, treating serum triglyceride as triolein (molar mass about 885.7 g/mol). A convention, since real triglyceride is a mixture
- mg/dL
- the unit the classification is defined in. A value entered in mmol/L is converted before grading, so the boundaries fall at the published mg/dL figures
- fasting
- the Endocrine Society bases the diagnosis on fasting triglycerides; non-fasting values run modestly higher
Worked example
Fasting triglyceride 640 mg/dL in a man with poorly controlled type 2 diabetes who drinks heavily.
Already in mg/dL, so no conversion: 640 mg/dL = 7.23 mmol/L
200 to 999 mg/dL → moderate hypertriglyceridaemia on the Endocrine Society scheme, graded for cardiovascular risk
But 640 is above 500, which NCEP ATP III calls very high and the 2018 AHA/ACC guideline called severe — the schemes disagree here
It is also above 400 mg/dL, so Friedewald LDL is invalid on this sample; use Sampson-NIH or non-HDL cholesterol
Secondary causes — the diabetes and the alcohol — are the first treatment, and they are what can take this into the pancreatitis range
Three classifications, and where each puts the pancreatitis line
| Triglyceride | Endocrine Society 2012 | NCEP ATP III | EAS/EFLM 2016 |
|---|---|---|---|
| Below 150 mg/dL (1.7) | Normal | Normal | Not flagged (fasting) |
| 150–199 mg/dL (1.7–2.3) | Mild | Borderline high | Flagged: 150 fasting, 175 non-fasting |
| 200–499 mg/dL (2.3–5.6) | Moderate | High | Flagged |
| 500–880 mg/dL (5.6–10) | Moderate | Very high | Flagged; non-fasting above 440 (5): repeat fasting |
| Above 880 mg/dL (10) | Moderate until 1,000 | Very high | Refer: chylomicronaemia, pancreatitis risk |
| 1,000–1,999 mg/dL (11.3–22.6) | Severe: pancreatitis risk | Very high | Refer |
| 2,000 mg/dL (22.6) or above | Very severe: pancreatitis risk | Very high | Refer |
Estimating LDL at high triglycerides
| Method | Valid up to | Above that |
|---|---|---|
| Friedewald | Below 400 mg/dL (4.5 mmol/L) | Do not report |
| Sampson-NIH | 800 mg/dL | Direct LDL |
| Non-HDL cholesterol | No limit — nothing is estimated | — |
Two reasons to care about triglycerides, at two very different levels
A raised triglyceride matters for two unrelated reasons, and the classification is easier to use once they are separated. At modest elevations the triglyceride is a marker: it travels in very-low-density lipoproteins and their remnants, which carry cholesterol into the artery wall, and the risk is atherosclerotic. At very high levels the particles are chylomicrons, which are too large to enter the artery wall but can precipitate acute pancreatitis. The Endocrine Society's 2012 guideline builds its bands around exactly that split: mild (150 to 199 mg/dL) and moderate (200 to 999 mg/dL) hypertriglyceridaemia are graded for cardiovascular risk, and severe (1,000 to 1,999 mg/dL) and very severe (2,000 mg/dL or above) are graded for pancreatitis.
The management changes with the reason. In the cardiovascular bands the Endocrine Society makes non-HDL cholesterol the treatment target, because it captures the cholesterol in every atherogenic particle, and statins remain the foundation. In the pancreatitis bands the aim is to get the triglyceride down quickly: a very-low-fat diet, no alcohol, control of diabetes and other secondary causes, and a fibrate. A value in those bands with abdominal pain is an emergency until pancreatitis is excluded.
The pancreatitis line is not drawn in the same place by everyone. The Endocrine Society and the 2026 ACC/AHA guideline use 1,000 mg/dL (11.3 mmol/L). The 2016 EAS/EFLM consensus on lipid reporting asks laboratories to flag anything above 880 mg/dL (10 mmol/L) for referral. NCEP ATP III calls 500 mg/dL very high, and the 2018 AHA/ACC guideline called 500 mg/dL severe. This page grades on the Endocrine Society scheme and prints the other lines whenever a result falls between them.
High triglycerides also break the arithmetic on the rest of the lipid profile. The Friedewald LDL calculator is invalid at 400 mg/dL or above; the Sampson-NIH LDL calculator remains usable to 800 mg/dL; above that a direct LDL is needed. The non-HDL cholesterol calculator needs no estimate at all. Convert units with the triglyceride unit converter, and use the non-fasting lipid profile interpreter to decide whether a non-fasting sample needs repeating.
Frequently asked questions
What triglyceride level causes pancreatitis?
The Endocrine Society and the 2026 ACC/AHA guideline place the pancreatitis risk from 1,000 mg/dL (11.3 mmol/L), with very severe hypertriglyceridaemia from 2,000 mg/dL (22.6 mmol/L). The EAS/EFLM lipid-reporting consensus flags above 880 mg/dL (10 mmol/L) for referral as chylomicronaemia with a high risk of pancreatitis.
Which triglyceride bands are about heart disease, and which about pancreatitis?
On the Endocrine Society classification, mild (150 to 199 mg/dL) and moderate (200 to 999 mg/dL) are about cardiovascular risk, and the target there is non-HDL cholesterol. Severe (1,000 to 1,999 mg/dL) and very severe (2,000 mg/dL or above) are about pancreatitis.
Can I calculate LDL cholesterol with high triglycerides?
Not with Friedewald at 400 mg/dL (4.5 mmol/L) or above. The Sampson-NIH equation is validated to 800 mg/dL. Above that, request a direct LDL, or use non-HDL cholesterol, which is measured rather than estimated.
Does a triglyceride need to be fasting?
For diagnosing hypertriglyceridaemia the Endocrine Society uses a fasting sample. For routine screening the EAS/EFLM consensus accepts non-fasting samples, and suggests repeating fasting if a non-fasting triglyceride is above 5 mmol/L (440 mg/dL).
Related calculators
References
- Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969–2989.
- Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points — a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944–1958.
- National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. Published online 13 March 2026. doi:10.1016/j.jacc.2025.11.016. Also in Circulation, doi:10.1161/CIR.0000000000001423.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC multisociety guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082–e1143. Superseded by the 2026 ACC/AHA dyslipidemia guideline.
- Sampson M, Ling C, Sun Q, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540–548.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.